These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 30900137)

  • 1. Quality of life during and after adjuvant anthracycline-taxane-based chemotherapy with or without Gemcitabine in high-risk early breast cancer: results of the SUCCESS A trial.
    Cámara RJA; Schwentner L; Friedl TWP; Deniz M; Fink V; Lato K; Widschwendter P; Rack B; Janni W; Singer S; Bekes I
    Breast Cancer Res Treat; 2019 Jun; 175(3):627-635. PubMed ID: 30900137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Impact of Age on Quality of Life in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Comparative Analysis From the Prospective Multicenter Randomized ADEBAR trial.
    Leinert E; Singer S; Janni W; Harbeck N; Weissenbacher T; Rack B; Augustin D; Wischnik A; Kiechle M; Ettl J; Fink V; Schwentner L; Eichler M
    Clin Breast Cancer; 2017 Apr; 17(2):100-106. PubMed ID: 27884722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low dose gemcitabine plus cisplatin in a weekly-based regimen as salvage therapy for relapsed breast cancer after taxane-anthracycline-containing regimens.
    Sánchez-Escribano Morcuende R; Alés-Martínez JE; Aramburo González PM
    Clin Transl Oncol; 2007 Jul; 9(7):459-64. PubMed ID: 17652060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem).
    McCarthy N; Boyle F; Zdenkowski N; Bull J; Leong E; Simpson A; Kannourakis G; Francis PA; Chirgwin J; Abdi E; Gebski V; Veillard AS; Zannino D; Wilcken N; Reaby L; Lindsay DF; Badger HD; Forbes JF;
    Breast; 2014 Apr; 23(2):142-51. PubMed ID: 24393617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer.
    Zaheed M; Wilcken N; Willson ML; O'Connell DL; Goodwin A
    Cochrane Database Syst Rev; 2019 Feb; 2(2):CD012873. PubMed ID: 30776132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroup.
    D'Hondt V; Canon JL; Roca L; Levy C; Pierga JY; Le Du F; Campone M; Desmoulins I; Goncalves A; Debled M; Rios M; Ferrero JM; Serin D; Hardy-Bessard AC; Piot G; Brain E; Dohollou N; Orfeuvre H; Lemonnier J; Roché H; Delaloge S; Dalenc F
    Eur J Cancer; 2019 Nov; 122():91-100. PubMed ID: 31634648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine and platinum combinations in patients with breast cancer previously treated with anthracyclines and/or taxanes.
    Perez EA
    Clin Breast Cancer; 2004 Jan; 4 Suppl 3():S113-6. PubMed ID: 14754468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High efficacy of gemcitabine and cisplatin in patients with predominantly anthracycline- and taxane-pretreated metastatic breast cancer.
    Heinemann V; Stemmler HJ; Wohlrab A; Bosse D; Losem C; Kahlert S; Rauthe G
    Cancer Chemother Pharmacol; 2006 May; 57(5):640-6. PubMed ID: 16163537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial.
    Sparano JA; Gray RJ; Makower DF; Albain KS; Saphner TJ; Badve SS; Wagner LI; Kaklamani VG; Keane MM; Gomez HL; Reddy PS; Goggins TF; Mayer IA; Toppmeyer DL; Brufsky AM; Goetz MP; Berenberg JL; Mahalcioiu C; Desbiens C; Hayes DF; Dees EC; Geyer CE; Olson JA; Wood WC; Lively T; Paik S; Ellis MJ; Abrams J; Sledge GW
    JAMA Oncol; 2020 Mar; 6(3):367-374. PubMed ID: 31566680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials.
    ;
    Lancet; 2023 Apr; 401(10384):1277-1292. PubMed ID: 37061269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biweekly administration of gemcitabine and cisplatin chemotherapy in patients with anthracycline and taxane-pretreated metastatic breast cancer.
    Tas F; Guney N; Derin D; Camlica H; Aydiner A; Topuz E
    Invest New Drugs; 2008 Aug; 26(4):363-8. PubMed ID: 18165864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gefitinib in combination with gemcitabine and vinorelbine in patients with metastatic breast cancer pre-treated with taxane and anthracycline chemotherapy: a phase I/II trial.
    Gioulbasanis I; Saridaki Z; Kalykaki A; Vamvakas L; Kalbakis K; Ignatiadis M; Amarantidis K; Kakolyris S; Georgoulias V; Mavroudis D
    Anticancer Res; 2008; 28(5B):3019-25. PubMed ID: 19031950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I-II study on a gemcitabine-cyclophosphamide-fluorouracil/folinic acid triplet combination in anthracycline- and taxane-refractory breast cancer patients.
    Frasci G; D'Aiuto G; Comella P; Thomas R; Capasso I; Botti G; Cortino GR; Di Bonito M; Rubulotta R; Vallone P; Comella G
    Oncology; 2002; 62(1):25-32. PubMed ID: 11810040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer.
    Dong N; Wu Y; Song C; Wang M; Jiao Y; Zhang S
    J BUON; 2020; 25(3):1348-1353. PubMed ID: 32862575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
    Ward S; Simpson E; Davis S; Hind D; Rees A; Wilkinson A
    Health Technol Assess; 2007 Oct; 11(40):1-144. PubMed ID: 17903394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane.
    Modi S; Currie VE; Seidman AD; Bach AM; Panageas KS; Theodoulou M; Moasser MM; D'Andrea GM; Lake DE; Choi J; Norton L; Hudis CA
    Clin Breast Cancer; 2005 Apr; 6(1):55-60. PubMed ID: 15899073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized trial comparing adjuvant chemotherapy with gemcitabine plus cisplatin with docetaxel plus cisplatin in patients with completely resected non-small-cell lung cancer with quality of life as the primary objective.
    Barlesi F; Chouaid C; Crequit J; Le Caer H; Pujol JL; Legodec J; Vergnenegre A; Le Treut J; Fabre-Guillevin E; Loundou A; Auquier P; Simeoni MC; Thomas PA
    Interact Cardiovasc Thorac Surg; 2015 Jun; 20(6):783-90. PubMed ID: 25765952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cisplatin plus gemcitabine chemotherapy in taxane/anthracycline-resistant metastatic breast cancer.
    Somali I; Alacacioglu A; Tarhan MO; Meydan N; Erten C; Usalp S; Yilmaz U
    Chemotherapy; 2009; 55(3):155-60. PubMed ID: 19390188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine, anthracycline, and taxane combinations for advanced breast cancer.
    Zielinski CC
    Oncology (Williston Park); 2003 Dec; 17(12 Suppl 14):36-40. PubMed ID: 14768404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.